ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
The collaboration will focus on the development and implementation ofcontinuous process technologies from research to full-scale production. Thepurpose of the project is to study the utilization and application ofThalesNano's integrated continuous process chemistry technologies within thesanofi-aventis drug R&D process from discovery to API production.
"We are delighted to work with sanofi-aventis R&D who have always been atthe forefront of applying new methods and technologies to improve the drugdiscovery and development process," said Dr. Laszlo Urge, CEO of ThalesNanoInc. "The ThalesNano continuous process technology is already wellestablished in the discovery labs of the life sciences industry. Taking it toprocess scale promises tremendous benefits for our customers in terms ofreducing development time, increasing cost efficiency and minimizingenvironmental impact."
Dr. Christophe Daubie, head of Chemical Development for Paris area atsanofi-aventis R&D said: "this collaboration is important also because itenters into the scope of sanofi-aventis R&D strategy in terms of our constantinvolvement in safety considerations, quality improvement of our processeswith respect to Environmental and Industrial Hygiene aspects, including GreenChemistry."
Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. "Thebenefits of continuous process chemistry over conventional batch chemistryincludes the rapid synthesis of organic compounds, in particular under untilnow unrealizable hazardous reaction conditions. Further benefits includeGreen Chemistry by minimizing waste, energy consumption and raw material use,lab automation, and rapid scale-up from mg to kg quantities, which reducesCAPEX and OPEX while speeding time to market."
For more information please go to: http://www.thalesnano.com
About ThalesNano Inc.:
ThalesNano is a world-leading provider of continuous process chemistryinstruments in the rapidly developing market of laboratory and process scaleflow reactors. The company has the widest portfolio of bench-top continuousprocess instruments. Its R&D 100 award winning H-Cube(R) continuous-flowhydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) areused in hundreds of laboratories in four continents and have become the newindustry standard for hydrogenation.
Sanofi-aventis, a leading global pharmaceutical company, discovers,develops and distributes therapeutic solutions to improve the lives ofeveryone.
SOURCE Thalesnano Nanotechnology Inc
You May Also Like